Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study
Open Access
- 13 November 2023
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-7
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (No. 82270178, 82070133)
- Natural Science Foundation of Guangdong Province (No. 2023A1515010111, 2021A1515012103)
This publication has 21 references indexed in Scilit:
- Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patientsBlood, 2019
- ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaNature Communications, 2017
- Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangementHaematologica, 2014
- Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemiaPediatric Blood & Cancer, 2014
- High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcomeLeukemia, 2014
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trialBlood, 2013
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trialBlood, 2012
- C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in miceProceedings of the National Academy of Sciences, 2011
- AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to GleevecProceedings of the National Academy of Sciences, 2005
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002